LLY241129P665000
- 0.25
- 0.000.00%
Eli Lilly and Co Newsroom
Short Stock Ideas From Each Sector With Earnings Quality in the Bottom 20%
U.S. stocks early market | Core PCE has the largest increase since April of this year! Spot gold briefly dropped; quantum computing concept stocks are booming! QUBT and RGTI rose by 10%, and Quantum once triggered a circuit breaker.
The market continues to focus on Trump's tariff policy and cabinet composition. The actual GDP growth rate of the United States in the third quarter slowed down compared to the second quarter.
Eli Lilly's Flortaucipir Approved by UK Regulator to Test for Alzheimer's Disease
Express News | Mhra: Approves Flortaucipir (Tauvid) for Adults Showing Signs of Cognitive Impairment for Alzheimer’s Disease
Amgen's Obesity Candidate MariTide Must Mitigate Tolerability Issues to Compete With Blockbuster Tirzepatide, Truist Says
Erste Group Downgrades Eli Lilly and Co(LLY.US) to Hold Rating
Trump Taps Jay Bhattacharya to Lead National Institutes of Health
Wells Fargo Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,000
US stocks unusual movement | Amgen continued to fall by more than 2.6% before the market opened, announcing that the weight loss drug trial effect is comparable to eli lilly and co's Zepbound but with more side effects.
Glonghui, November 27 - Amgen (AMGN.US) continued to decline more than 2.6% in pre-market trading, reporting $272.64. The stock fell 4.76% on Tuesday. In terms of news, Amgen announced on Tuesday that in a year-long trial, non-diabetic patients taking the weight loss drug MariTide once a month or less could lose up to 20% of their weight. Analysts pointed out that this is comparable to the effects of Eli Lilly and Co's Zepbound at its highest dose. However, data shows that the side effects of MariTide are greater than those of Zepbound, with about 11% of patients dropping out due to side effects.
Is weight loss medication including in usa medical insurance, becoming the strongest 'roadblock' for the Trump team?
"Weight loss duo" leads significant increase.
Hong Kong stocks move | Laika Pharmaceutical-B (02105) rose more than 11% in early trading. Overnight, U.S. stocks in the weight loss drugs sector experienced a broad rise. The company has launched clinical cooperation with eli lilly and co on a new weigh
Lai Kai Pharmaceutical-B (02105) rose more than 11% in the morning, as of the time of publication, it increased by 9.79%, reaching 17.04 Hong Kong dollars, with a turnover of 30.7419 million Hong Kong dollars.
Futu Morning Report | The US stock market party continues! The s&p 500 index has risen for seven consecutive days, setting a new historical high; Federal Reserve meeting minutes: future interest rate cuts will be cautious, and the end of monetary easing i
Market response to Trump's tariff threats: auto stocks wail, the Canadian dollar hits a four-year low, and the Mexican peso plunges nearly 3%; dell technologies drops over 10% after hours, with total net revenue for the third quarter at 24.37 billion USD, below analyst expectations.
Tradepulse Power Inflow Alert: Eli Lilly & Company Climbs Over 22 Points After Alert
Eli Lilly and Co (LLY.US) cancels double injections, brewing super BD for muscle gain and fat loss.
GLP-1 dual heroes Semaglutide and Tirzepatide, the total sales in 2024 will exceed $40 billion, leading to a huge demand in the muscle-building drug market.
Transaction volume TOP 20 | Bitcoin falls below 0.091 million dollars, microstrategy drops over 12%; eli lilly and co rises over 4%, the Biden administration plans to include weight loss drugs in the health insurance subsidy program.
On Tuesday, the stock trading volume leader was nvidia, which rose by 0.66% with a trading volume of 25.738 billion USD. nvidia announced on Monday the launch of its music-generating AI model, Fugatto, claiming it to be the "most flexible sound machine in the world," capable of precisely controlling sound generation. nvidia stated that this tool is like a "swiss army knife" for the sound field, being able to create music, modify sounds, and flexibly mix various music, vocals, and sound effects, even generating unprecedented sounds. The second place went to Tesla, which fell by 0.11% with a trading volume of 20.929 billion USD. ubs group published a bearish research report on Tesla. The institutions stated,
Amgen weight loss drugs have a remarkable effect of reducing 20% body weight, but with relatively high side effects, leading to a temporary large drop of over 12% during trading hours.
Although the weight loss effect of amgen's MariTide drug met expectations, the high side effects, lower than eli lilly and co's Zepbound, and the trial results falling below Wall Street's high expectations, led to amgen's stock price plunging over 12.3% on Tuesday, far behind eli lilly and co and novo-nordisk a/s, which benefited from the Biden policy rise at the same time. In a one-year trial, MariTide helped non-diabetic patients lose up to 20% of their weight, comparable to the maximum dose effect of eli lilly's Zepbound. However, the side effects are significant, with about 11% of patients dropping out of the trial due to side effects, higher than eli lilly's 7%.
US stocks closed | The three major indices rose together, with Dow Jones and S&P hitting new highs; tariff threats dragged down auto stocks, general motors fell 9%
Waiting for PCE inflation, the Fed's November minutes support gradual rate cuts, temporarily suppressing US bond yields and the dollar while gold rallies. The Dow turns higher at the end of the day, hitting new highs for three consecutive days, while small cap stocks fall from the highest level in six days, with chip stocks down more than 1%, but nvidia rebounds by 0.7%. Tesla reverses its decline, Nio falls by 7.7%, Amgen's weight loss drug once fell by more than 12%, and Dell falls more than 9% after hours.
U.S. stocks closed: The Dow and S&P reached all-time highs, while general motors plunged nearly 9%.
① Most technology giants rose, only Tesla fell; ② Eli Lilly and Co rose by 4.5%, as Biden proposed health insurance coverage for weight loss drugs; ③ The Chinese concept stock Jinlong Index fell by 0.8%, Nio fell by 7.7%; ④ Apple proposed to increase investment by 0.1 billion US dollars to seek to lift the sales ban, but was rejected by the Indonesian government.
Eli Lilly and Co Options Spot-On: On November 26th, 120.59K Contracts Were Traded, With 340.93K Open Interest
On November 26th ET, $Eli Lilly and Co(LLY.US)$ had active options trading, with a total trading volume of 120.59K options for the day, of which put options accounted for 30.36% of the total
The U.S. government proposed that medical insurance cover the cost of weight loss drugs, and eli lilly and co (LLY.US) rose by 5%.
Diabetes and weight-loss drug manufacturers eli lilly and co (LLY.US) and novo-nordisk a/s (NVO.US) saw their stock prices rise by 5% and 2% respectively on Tuesday, as the US government introduced a new regulation allowing medical insurance and Medicaid to cover the costs of weight-loss treatment for obese patients. The government stated that millions of obese Americans will be eligible to receive coverage for weight-loss medications such as Wegovy or Ozempic under medical insurance or Medicaid, with fiscal expenditures reaching up to $35 billion in the next decade.